Product Name: Mircera [methoxy polyethylene glycol-epoetin beta]
Date of Report: To be Published
Phase: II
A Study of Mircera in Anemic Patients With Non-Small Cell Lung Cancer Receiving Chemotherapy
Product Name: Mircera [methoxy polyethylene glycol-epoetin beta]
Date of Report: To be Published
Phase: III
A Study of Intravenous or Subcutaneous Mircera in Chronic Kidney Disease Patients With Renal Anemia
Product Name: Mircera [methoxy polyethylene glycol-epoetin beta]
Date of Report: To be Published
Phase: II
A Study of Mircera in Patients With Non-Hodgkin’s Lymphoma and Anemia
Product Name: Mircera [methoxy polyethylene glycol-epoetin beta]
Date of Report: 5/26/2005
Phase: II
An open label, randomized, multi-center, multiple dose trial to investigate the efficacy and safety of subcutaneous injections of Mircera at different dosing intervals in patients with chronic renal anemia who are not on renal replacement therapy.
Product Name: Mircera [methoxy polyethylene glycol-epoetin beta]
Date of Report: 2/1/2006
Phase: II
An open-label, multi-center, multiple dose trial to investigate the efficacy and safety of subcutaneous injections of Mircera at different dosing intervals in dialysis patients with chronic renal anemia.
Product Name: Mircera [methoxy polyethylene glycol-epoetin beta]
Date of Report: 3/1/2006
Phase: II
An open-label, multicenter, randomized study to determine dose conversion factors at different frequencies of administration after switching from maintenance treatment with subcutaneous epoetin alfa or beta to maintenance treatment with subcutaneous Mircera in dialysis patients with chronic renal anemia.
Product Name: Mircera [methoxy polyethylene glycol-epoetin beta]
Date of Report: 3/1/2006
Phase: II
An open-label, multi-center, randomized study to determine dose conversion factors at different frequencies of administration after switching from maintenance treatment with intravenous epoetin alfa to maintenance treatment with intravenous Mircera in hemodialysis patients with chronic renal anemia.
Product Name: Mircera [methoxy polyethylene glycol-epoetin beta]
Date of Report: 3/1/2006
Phase: III
A randomized, controlled, open-label, multi-center, parallel-group study to demonstrate the efficacy and safety of Mircera when administered with pre-filled syringes for the maintenance treatment of anemia in patients with chronic kidney disease who are on dialysis.
Product Name: Mircera [methoxy polyethylene glycol-epoetin beta]
Date of Report: 3/1/2006
Phase: III
A randomized, controlled, open-label, multi-center, parallel-group study to demonstrate the efficacy and safety of Mircera when administered intravenously for the maintenance treatment of anemia in patients with chronic kidney disease who are on dialysis.
Product Name: Mircera [methoxy polyethylene glycol-epoetin beta]
Date of Report: 3/1/2006
Phase: III
A randomized, controlled, open-label, multi-center, parallel-group study to demonstrate the efficacy and safety of Mircera when administered subcutaneously for the maintenance treatment of anemia in patients with chronic kidney disease who are on dialysis.
Product Name: Mircera [methoxy polyethylene glycol-epoetin beta]
Date of Report: 3/1/2006
Phase: III
A randomized, controlled, open-label, multi-center, parallel-group study to demonstrate the efficacy and safety of Mircera when administered intravenously for the maintenance treatment of anemia in patients with chronic kidney disease who are on dialysis.
Product Name: Mircera [methoxy polyethylene glycol-epoetin beta]
Date of Report: 3/1/2006
Phase: III
An open-label, randomized, multi-center, parallel group study to demonstrate correction of anemia using subcutaneous injections of Mircera in patients with chronic kidney disease who are not on dialysis.
Product Name: Mircera [methoxy polyethylene glycol-epoetin beta]
Date of Report: 3/1/2006
Phase: III
An open-label, randomized, multi-center, parallel group study to demonstrate correction of anemia using intravenous injections of Mircera in patients with chronic kidney disease who are on dialysis.
Product Name: Mircera [methoxy polyethylene glycol-epoetin beta]
Date of Report: To be Published
Phase: II
A Study of Mircera in Anemic Patients With Non-Small Cell Lung Cancer Receiving First Line Chemotherapy.
Product Name: Mircera [methoxy polyethylene glycol-epoetin beta]
Date of Report: To be Published
Phase: III
A Study of Mircera in the Long Term Treatment of Patients With Renal Anemia.
Product Name: Mircera [methoxy polyethylene glycol-epoetin beta]
Date of Report: To be Published
Phase: II
A Study of Mircera in Anemic Patients With Multiple Myeloma.
Product Name: Mircera [methoxy polyethylene glycol-epoetin beta]
Date of Report: To be Published
Phase: III
A Study of Mircera for the Maintenance Treatment of Anemia in Dialysis Patients.
Product Name: Mircera [methoxy polyethylene glycol-epoetin beta]
Date of Report: To be Published
Phase: III
A Study of Intravenous Mircera for the Treatment of Anemia in Dialysis Patients.
Product Name: Mircera [methoxy polyethylene glycol-epoetin beta]
Date of Report: To be Published
Phase: III
A Study Comparing Mircera and Epeotin Alfa for the Treatment of Anemia in Dialysis Patients With Chronic Kidney Disease.
Product Name: Mircera [methoxy polyethylene glycol-epoetin beta]
Date of Report: To be Published
Phase: III
A Study Comparing Mircera and Epoetin Beta for the Treatment of Anemia in Dialysis Patients With Chronic Kidney Disease.
Product Name: Mircera [methoxy polyethylene glycol-epoetin beta]
Date of Report: To be Published
Phase: III
A Study of Subcutaneous Mircera in Patients With Chronic Kidney Disease, Not on Dialysis.
Product Name: Mircera [methoxy polyethylene glycol-epoetin beta]
Date of Report: To be Published
Phase: III
A Study of Subcutaneous Mircera for the Treatment of Anemia in Peritoneal Dialysis Patients.
Product Name: Mircera [methoxy polyethylene glycol-epoetin beta]
Date of Report: To be Published
Phase: III
A Study of Mircera in Hemoglobin Control of Patients Transitioning to Dialysis.
Product Name: Mircera [methoxy polyethylene glycol-epoetin beta]
Date of Report: To be Published
Phase: III
A Study of Subcutaneous Mircera for the Treatment of Anemia in Pre-Dialysis Patients WIth Chronic Kidney Disease.
Product Name: Mircera [methoxy polyethylene glycol-epoetin beta]
Date of Report: To be Published
Phase: III
LATINO Study: A Study of Mircera for the Maintenance Treatment of Dialysis Patients With Chronic Renal Anemia.
Product Name: Mircera [methoxy polyethylene glycol-epoetin beta]
Date of Report: To be Published
Phase: III
A Study of Subcutaneous Mircera for the Maintenance Treatment of Pre-Dialysis Patients With Chronic Renal Anemia.
Product Name: Mircera [methoxy polyethylene glycol-epoetin beta]
Date of Report: To be Published
Phase: III
A Study of Mircera for the Maintenance Treatment of Patients With Chronic Renal Anemia.
Product Name: Mircera [methoxy polyethylene glycol-epoetin beta]
Date of Report: To be Published
Phase: III
A Study of Intravenous Mircera for the Correction of Anemia in Dialysis Patients.
Product Name: Mircera [methoxy polyethylene glycol-epoetin beta]
Date of Report: To be Published
Phase: III
MIRACLE Study: A Study of Once-Monthly Intravenous Mircera in Hemodialysis Patients With Chronic Renal Anemia.
Product Name: Mircera [methoxy polyethylene glycol-epoetin beta]
Date of Report: To be Published
Phase: III
A Study of Subcutaneous Mircera in Patients With Chronic Kidney Disease Not Treated With ESA or on Dialysis.
Product Name: Mircera [methoxy polyethylene glycol-epoetin beta]
Date of Report: To be Published
Phase: III
A Study of Subcutaneous Mircera Once Monthly in the Treatment of Anemia in Patients With Chronic Kidney Disease Not on Dialysis.
Product Name: Mircera [methoxy polyethylene glycol-epoetin beta]
Date of Report: To be Published
Phase: III
A Study of Subcutaneous Mircera for the Maintenance Treatment of Dialysis Patients With Chronic Renal Anemia.
Product Name: Mircera [methoxy polyethylene glycol-epoetin beta]
Date of Report: To be Published
Phase: III
A Study of Intravenous Mircera in Dialysis Patients With Chronic Renal Disease and Anemia.
Product Name: Mircera [methoxy polyethylene glycol-epoetin beta]
Date of Report: To be Published
Phase: III
A Study of Subcuteneous Mircera for the Treatment of Anemia in Pre-Dialysis Patients.
Product Name: Mircera [methoxy polyethylene glycol-epoetin beta]
Date of Report: To be Published
Phase: IV
A Study of Subcutaneous Mircera, Versus no ESA Therapy, in the Treatment of Anemia in Patients With Chronic Kidney Disease After Kidney Transplant.
Product Name: Mircera [methoxy polyethylene glycol-epoetin beta]
Date of Report: To be Published
Phase: III
A Study of Intravenous Mircera for the Maintenance Treatment of Hemodialysis Patients With Chronic Renal Anemia.
Product Name: Mircera [methoxy polyethylene glycol-epoetin beta]
Date of Report: To be Published
Phase: III
A Study Comparing Subcutaneous Mircera and Darbepoetin Alfa for the Maintenance Treatment of Anemia in Kidney Transplant Patients.
Product Name: Mircera [methoxy polyethylene glycol-epoetin beta]
Date of Report: To be Published
Phase: III
A Study of Subcutaneous Mircera for the Maintenance Treatment of Patients With Chronic Renal Anemia Not on Dialysis.
Product Name: Mircera [methoxy polyethylene glycol-epoetin beta]
Date of Report: To be Published
Phase: III
A Study of Intravenous Mircera in Hemodialysis Patients With Chronic Renal Anemia.
Product Name: Mircera [methoxy polyethylene glycol-epoetin beta]
Date of Report: To be Published
Phase: III
A Study of Intravenous Mircera for the Maintenance Treatment of Dialysis Patients With Chronic Renal Anemia.
Product Name: Mircera [methoxy polyethylene glycol-epoetin beta]
Date of Report: To be Published
Phase: IV
A Study of Subcutaneous Mircera for the Maintenance Treatment of Patients With Chronic Renal Anemia Not Receiving ESA Treatment or Dialysis.
Product Name: Mircera [methoxy polyethylene glycol-epoetin beta]
Date of Report: To be Published
Phase: III
A Study of Subcutaneous Mircera For The Maintenance Treatment of Anemia in Patients With Chronic Kidney Disease Not on Dialysis.
Product Name: Mircera [methoxy polyethylene glycol-epoetin beta]
Date of Report: To be Published
Phase: III
A Study of Intravenous Mircera in Patients With Chronic Renal Anemia Who Are on Dialysis.
Product Name: Mircera [methoxy polyethylene glycol-epoetin beta]
Date of Report: To be Published
Phase: III
A Study of Monthly Subcutaneous Mircera for the Treatment of Chronic Renal Anemia in Predialysis Patients Not Treated With ESA.
Product Name: Mircera [methoxy polyethylene glycol-epoetin beta]
Date of Report: To be Published
Phase: III
A Study of Once-Monthly Subcutaneous Mircera for the Treatment of Chronic Renal Anemia in Pre-Dialysis Patients Not Currently Treated With ESA.
Product Name: Mircera [methoxy polyethylene glycol-epoetin beta]
Date of Report: To be Published
Phase: III
CARISMA Study: A Study of Monthly Intravenous Mircera in Hemodialysis Patients With Chronic Renal Anemia.
Product Name: Mircera [methoxy polyethylene glycol-epoetin beta]
Date of Report: To be Published
Phase: II
A Study of Intravenous Mircera for the Treatment of Anemia in Pediatric Patients on Hemodialysis
Product Name: Mircera [methoxy polyethylene glycol-epoetin beta]
Date of Report: To be Published
Phase: III
A Study of Once Monthly Intravenous or Subcutaneous Mircera in Patients With Chronic Kidney Disease on Hemodialysis.
Product Name: Mircera [methoxy polyethylene glycol-epoetin beta]
Date of Report: To be Published
Phase: III
MISTRAL Study: A Study of Monthly Subcutaneous Mircera for Maintenance Treatment of Patients WIth Chronic Kidney Disease on Peritoneal Dialysis.
Product Name: Mircera [methoxy polyethylene glycol-epoetin beta]
Date of Report: To be Published
Phase: IV
A Study of the Safety, Tolerability and Efficacy With Respect to the Maintenance of Hemoglobin Levels of Once Monthly Mircera in Dialysis Patients With Chronic Renal Anemia.
Product Name: Mircera [methoxy polyethylene glycol-epoetin beta]
Date of Report: To be Published
Phase: IV
A Study of the Safety, Tolerability and Efficacy With Respect to Raising Hemoglobin Levels of Two-Weekly Mircera in Dialysis Patients With Chronic Renal Anemia Not Receiving ESA Therapy.
Product Name: Mircera [methoxy polyethylene glycol-epoetin beta]
Date of Report: To be Published
Phase: III
A Study Comparing Maintenance of Hemoglobin Levels, Safety and Tolerability of Once Every 4 Weeks Mircera Versus Epoetin Beta in Dialysis Patients With Chronic Renal Anemia.
Product Name: Mircera [methoxy polyethylene glycol-epoetin beta]
Date of Report: To be Published
Phase: III
ORION Study: A Study of Monthly Subsutaneous Mircera in Predialysis Patients with Chronic Renal Anemia
Product Name: Mircera [methoxy polyethylene glycol-epoetin beta]
Date of Report: To be Published
Phase: IV
A Study of All-Cause Mortality and Cardiovascular Morbidity in CKD Patients on Dialysis and Those Not on Renal Replacement Therapy Receiving Mircera or Reference ESAs.
